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Abstract
Aims The Liraglutide Effect and Action in Diabetes 6 trial was an open-label trial comparing liraglutide with exenatide as an
‘add-on’ to metformin and⁄or sulphonylurea.
Methods Patients with Type 2 diabetes were randomized to liraglutide 1.8 mg once daily or exenatide 10 lgt w i c ed a i l yf o r
26 weeks. This was followed by a 14-week extension phase, in which all patients received liraglutide 1.8 mg once daily.
Results Patient-reportedoutcomesweremeasuredin379patientsusingDiabetesTreatmentSatisfactionQuestionnairestatus
(DTSQs) and DTSQ change (DTSQc). The change in overall treatment satisfaction (DTSQs score) from baseline at week 26
withliraglutidewas4.71andwithexentaidewas1.66[differencebetweengroups3.04(95% CI1.73–4.35),P < 0.0001].Five
of the six items on the DTSQs improved signiﬁcantly more with liraglutide than with exenatide (differences: current treatment
0.37, P = 0.0093; convenience 0.68, P < 0.0001; ﬂexibility 0.57, P = 0.0002; recommend 0.49, P = 0.0003; continue 0.66,
P = 0.0001). Patients perceived a greater reduction in hypoglycaemia at week 26 with liraglutide than with exenatide
[differenceinDTSQcscore0.48(0.08–0.89),P = 0.0193]andagreaterreductioninperceivedhyperglycaemia[difference0.74
(0.31–1.17), P = 0.0007]. During the extension phase, when all patients received liraglutide, DTSQs scores remained stable in
patients who continued on liraglutide and increased signiﬁcantly (P = 0.0026) in those switching from exenatide.
Conclusions Theseresultsdemonstratesigniﬁcantimprovementsinpatients’treatmentsatisfactionwithliraglutidecompared
with exenatide.
Diabet. Med. 28, 715–723 (2011)
Keywords exenatide, liraglutide, patient-reported outcomes, Type 2 diabetes
Abbreviations DTSQc, Diabetes Treatment Satisfaction Questionnaire change version; DTSQs, Diabetes Treatment
Satisfaction Questionnaire status version; GLP-1, glucagon-like peptide 1; LEAD 6, Liraglutide Effect and Action in
Diabetes 6
Introduction
The negative impact of Type 2 diabetes on health status is well
established [1]. A number of factors contribute towards changes
in patient-reported outcome measures for people with Type 2
diabetes.These include:
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symptom distress, general perceived health and cognitive
functioning [2];
(ii) overweight or obesity, which has an adverse effect on
mobility, self-care and usual activities and causes
pain⁄discomfort [3,4];
(iii) treatment side effects such as hypoglycaemia, which can
affect all domains⁄sections of the measure of functional
health and well-being (Short Form 36) [5];
(iv) the presence of diabetes complications, which is
associated with depression, fatigue, less vigour, and
reduced mobility, self-care and usual activities [6].
Improvements in these factors will generally translate into
improved health status [7]. In addition to measuring the clinical
efﬁcacy and safety of any novel anti-diabetes drug, patient-
reported outcome measures are important to assess the patients’
perceptions of their condition and the beneﬁts of treatment. Thus,
patient-reported outcome measures may be important in
complementing clinical measures of treatment efﬁcacy and safety.
Glucagon-like peptide 1 (GLP-1) analogues represent a new
class of anti-diabetes medications that, through their glucose-
dependent mechanism of action, may avoid some of the
limitations of earlier-generation agents. They are not associated
with oedema and have a low incidence of hypoglycaemia. In
addition to providing glucoregulatory effects, weight loss is
common among patients receiving GLP-1 analogues [8]. In a
recent consensus statement by the American Diabetes
Association⁄European Association for the Study of Diabetes,
agonists of the GLP-1 receptor are listed among the agents that
canbeaddedtometformintherapywhenweightlossisimportant
[9].
Two agonists of the GLP-1 receptor have been approved for
treating Type 2 diabetes. Exenatide (Eli Lilly and Company,
Indianapolis, IN, USA) requires twice-daily subcutaneous
administration and has demonstrated efﬁcacy with respect to
glycaemic control and weight loss [9,10]. Liraglutide (Novo
Nordisk,Bagsværd,Denmark)isahumanGLP-1agonist,which
is effective with once-daily administration, can be injected
without regard to timing of meals, and is associated with weight
loss and a low risk of hypoglycaemia [8,10–13]. The risk of
hypoglycaemia and weight gain have been recognized as
important factors in making treatment decisions [14] and
reductions may improve health status. Data from a trial
comparing liraglutide with glimepiride suggest that treatment
with liraglutide improves patient-reported outcomes and weight
assessments compared with glimepiride [15].
The Liraglutide Effect and Action in Diabetes 6 (LEAD 6)
trial was a large, phase-IIIb clinical trial comparing the efﬁcacy
and safety of either liraglutide or exenatide in combination with
metformin and⁄or sulphonylurea in Type 2 diabetes. Greater
reductions in HbA1c (P < 0.0001), a lower incidence of
hypoglycaemia and similar reductions in weight were observed
with liraglutide 1.8 mg once daily compared with exenatide
10 lg twice daily [16]. Patient-reported outcome measures were
assessed in LEAD 6 by the Diabetes Treatment Satisfaction
Questionnaire (DTSQ) [17] to obtain information on treatment
satisfaction with liraglutide and exenatide. The results from
these patient-reported outcome measure analyses are reported
here.
Methods
The methodology of LEAD 6 is summarized here and described
fully elsewhere [16]. LEAD 6 was conducted at 132 sites in 15
countries, in accordance with the Declaration of Helsinki and its
amendments, and was approved by all relevant health
authorities. All participants in the trial gave written informed
consent before taking part.
Patients
LEAD 6 included patients aged 18–80 years with Type 2
diabetes who were receiving a stable regimen of metformin,
sulphonylurea or both for at least 3 months, and had HbA1c
values of 7.0–11.0% (53–97 mmol⁄m o l )a n daB M I
£ 45 kg⁄m
2. Patients had no previous treatment with insulin,
exenatide or liraglutide.
Study design
The trial was a randomized, open-label, parallel-group
comparison of liraglutide 1.8 mg once daily with exenatide
10 lg twice daily for 26 weeks. Both treatments were added to
an existing treatment regimen that included metformin,
sulphonylurea or both (Fig. 1). After randomization, liraglutide
was escalated to the 1.8-mg dose in weekly 0.6-mg increments
(i.e. the starting dose of 0.6 mg was increased after 1 week to
1.2 mgandafter2 weeksto1.8 mg)andexenatidewasescalated
up to the 10-lg dose after 4 weeks of 5 lg twice daily. Patients
then remained on these maximum recommended doses for
22–24weeks.Thiswasfollowedbyanongoingnon-randomized
extension phase with endpoint assessment at 14 weeks, during
which all patients received liraglutide 1.8 mg once daily; so
patients on exenatide 10 lg twice daily were switched to
liraglutide 1.8 mg once daily (Fig. 1). The study, which began
on 24 August 2007, was completed on 9 April 2008.
Assessments
During the trial, patients were assessed for efﬁcacy and safety
variables. Efﬁcacy variables included HbA1c, weight, waist and
hip circumference, fasting plasma glucose, self-measured fasting
plasma glucose and 7-point glucose proﬁle, B-cell function and
glucagon, fasting lipid proﬁle, blood pressure, cardiovascular
biomarkers and patient-reported outcome measures. Safety
variables included physical examination, pulse rate and
hypoglycaemic episodes; laboratory tests included haemato-
logical and biochemical measures, and measurement of
antibodies to liraglutide and exenatide.
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administered questionnaire, DTSQ [17], in eight of the
participating countries, which included Austria, Denmark,
Finland, Germany, Ireland, Poland, Romania and the USA.
The remaining countries were not included in the patient-
reported outcome sub-study because of lack of available
linguistic validated patient-reported outcome measures. The
DTSQ consists of two versions, both assessing treatment
satisfaction among patients, as well as the perceived frequency
of hyperglycaemia and hypoglycaemia. The DTSQs (status
version) measures status at a given time point and the DTSQc
(change version) measures changes over a period of time (i.e.
from baseline). Both of these versions of the DTSQ assess
treatment satisfaction by six items on ‘current treatment’,
‘convenience’, ‘ﬂexibility’, ‘understanding’, ‘recommend’ and
‘continue’. Perceived frequency of hyperglycaemia and
hypoglycaemia were measured by one item each. The
individual questions on the DTSQ were scored on a 7-point
Likert scale, from 0 to 6 in the DTSQs and from –3 to +3 in the
DTSQc. Scores for the six treatment satisfaction items were
summedtogiveatotalscoreof0to36fortheDTSQsand–18to
+18 for the DTSQc. A higher score denotes greater patient
satisfaction. The perceived frequency of hyperglycaemia and
hypoglycaemiaitemsscoresrangefrom0(‘noneofthetime’)to6
(‘most of the time’) in the DTSQs and from –3 (‘much less of the
time now’) to +3 (‘much more of the time now’) in the DTSQc.
The status version (DTSQs) was completed by patients at
baseline(randomization),week 26,week 34andweek 40andat
early withdrawal from the study; the change version (DTSQc)
was completed by patients at week 26 and at week 34 (for
perception of change from baseline until week 26 and from
week 26 to week 34) [17,18].
Statistical analyses
The detailed statistical analyses of efﬁcacy endpoints of LEAD 6
aredescribedelsewhere[16].Theprimaryendpointwasanalysed
using both the intention-to-treat and the per-protocol
populations, but patient-reported outcome analyses were
restricted to the intention-to-treat population (all randomized
participants who received at least one dose of the study drugs).
Missing data were replaced using the last-observation-carried-
forward approach, but forDTSQc data (which were collected at
week 26 only) observed cases only were included. For the
patient-reported outcome analyses, DTSQs endpoints were
analysed at week 26 using the standard ANCOVA model with
treatment, country and previous treatment as ﬁxed effects, and
DTSQcendpointswereanalysedusinganANCOVAmodelwith
treatment, country and previous treatment as ﬁxed effects and
baseline DTSQs as covariate.
Results
In LEAD 6, 464 patients were randomized and exposed to
treatment (intention-to-treat population); 233 received
liraglutide and 231 received exenatide in addition to their
existing treatment regimen [16] (Fig. 2). Patient-reported
outcome measures were assessed in 379 patients (82%). In the
fullstudypopulation,78patients(33intheliraglutidegroupand
45 in the exenatide group) failed to complete the randomization
portion of the study and were withdrawn (before entering the
extensionphase),primarilybecauseofadverseevents(Fig. 2).Of
these withdrawals, 26 patients in the liraglutide group and 40
patients in the exenatide group were in the subset of patients
assessedforpatient-reportedoutcomemeasuresandcompleteda
follow-up DTSQ at the time of withdrawal, but not at week 26
or subsequent visits.
The two treatment groups, the population in the main study
and the patient-reported outcome-assessed subgroup
population, were well matched in their baseline characteristics
(Table 1). Most patients were receiving a metformin⁄
sulphonylurea combination at enrolment, and these patients
had a longer mean duration of diabetes (9.5 years) than patients
receiving monotherapy with either drug (5.3 and 7.5 years for
those receiving metformin and sulphonylurea monotherapy,
respectively). The DTSQs scores indicated very similar baseline
levels of treatment satisfaction in the two randomized treatment
groups.
Adults 18–80 years 
with Type 2 diabetes
HbA1c:
7.0–11.0%
(53–97 mmol/mol) 
BMI ≤45 kg/m
2
Metformin
and/or sulphonylurea
10 µ µg b.i.d. 22 weeks
Liraglutide (n = 233)
0.6 mg q.d. 1 week 
1.2 mg q.d. 1 week 
Metformin and/or sulphonylurea
continued at pre-study dose
1.8 mg q.d. 24 weeks
Exenatide (n = 231)
5 µg b.i.d. 4 weeks
0.6mg OD  
1 week
1.8 mg q.d.14 weeks 
1.2mg OD 
1 week
Screening 26 weeks 14 weeks
FIGURE 1 Study design of Liraglutide Effect and Action in Diabetes 6 (LEAD 6).
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The results of LEAD 6 are presented in more detail elsewhere
[16]. The overall treatment satisfaction, as measured by the
DTSQs,wassimilarinthetwotreatmentgroupsatbaseline,but,
after 26 weeks of treatment, the DTSQs score increased more in
thegroupreceivingliraglutidethanthegroupreceivingexenatide
[from 27.4 to 32.1 in the liraglutide group, absolute change
4.71; and from 27.6 to 29.3 in the exenatide group, absolute
change1.66;intention-to-treat–lastobservation-carried-forward
population; difference between groups 3.04 (95% CI 1.73–
4.35),P < 0.0001].Theproportionofpatientsthatweresatisﬁed
overallwiththeirtreatment(predeﬁnedasanoverallscoreonthe
DTSQsof> 24)was91%intheliraglutidegroupand82%inthe
exenatidegroup[differencebetweengroups9.0%(95% CI1.2–
16.7%), P = 0.0192]. The DTSQc score, which measured the
change from baseline in a single score, conﬁrmed that levels of
treatment satisfaction were higher in the liraglutide group (mean
score 15.18) than in the exenatide group (mean score 13.30;
P = 0.0004 observed cases), and the proportion of ‘satisﬁed’
patients (deﬁned as an overall score on the DTSQc of > 6) was
94% in the liraglutide group and 86% in the exenatide group
[difference between groups 8.5% (95% CI 1.1–15.9%),
P = 0.0176]. During the extension phase of the trial, when all
patients switched to liraglutide 1.8 mg therapy, DTSQs scores
remained stable in patients who had received liraglutide in the
ﬁrst26 weeksofthetrialandincreasedsigniﬁcantly(P = 0.0026)
at week 40 in those who switched from exenatide to liraglutide
atweek 26(Fig. 3andTable 3).TheDTSQcscoresalsoshowed
improvements from week 26 to week 34 in patients switched
from exenatide treatment to liraglutide treatment.
The six items of the DTSQ were analysed, and the change in
DTSQs score frombaseline to week 26 was greaterin all aspects
of treatment satisfaction (‘satisfaction with treatment’,
‘convenience’, ‘ﬂexibility’, ‘recommend’ and ‘continue’) with
liraglutide than with exenatide, and all differences were
statistically signiﬁcant, except for the item measuring ‘satisﬁed
withdiabetesunderstanding’(Table 2).ResultsfromtheDTSQc
(observed cases) also showed greater improvements in all items
with liraglutide than with exenatide, except the item measuring
‘diabetesunderstanding’,whichwassimilarinthetwotreatment
groups (Table 2).
Patients receiving liraglutide perceived a greater reduction in
hypoglycaemia and hyperglycaemia from baseline to week 26
than patients receiving exenatide, according to the DTSQc but
not DTSQs scores (Table 2).
Discussion
This current analysis of the patient-reported outcome data
from LEAD 6 shows that liraglutide is also associated with
greater improvements in treatment satisfaction and less
Screened
n = 663
Randomized
N = 464
Liraglutide
n = 233*
Exenatide
n = 231†
Premature discontinuation during
randomization phase (n = 33)
Adverse event: n = 23
Lack of efficacy: n = 1
Protocol non-compliance: n = 4
Withdrawal criteria fulfilled: n = 1
Other: n = 4
Premature discontinuation during
randomization phase (n = 45)
Adverse event: n = 31
Protocol non-compliance: n = 3
Withdrawal criteria fulfilled: n = 1
Other: n = 10 
Completed study
n = 187
With PROMs assessed: n = 147
PROMs assessed (n = 192)
Discontinued during
randomization phase: n = 26
PROMs assessed (n = 187)
Discontinued during
randomization phase: n = 40
Completed study
n = 202
With PROMs assessed: n = 166
FIGURE 2 Patient disposition from screening until the end of the randomization phase (26 weeks) in Liraglutide Effect and Action in Diabetes 6 (LEAD 6).
*Intention-to-treat(ITT),per-protocol(PP)andsafetypopulationsintheliraglutidetreatmentgroupwere233,193and235,respectively.ITT,PPandsafety
populations in the exenatide treatment group were 231, 172 and 232, respectively. PROMs, patient-reported outcome measures.
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The extension phase of the trial shows that the level
of treatment satisfaction is signiﬁcantly increased when
patients are switched from exenatide treatment to liraglutide
treatment.
Glycaemiccontrolinpatientsreceivingoralanti-diabeticdrugs
for Type 2 diabetes eventually deteriorates and the patients may
suffer from frequent hypoglycaemia and weight gain [19].
Treatment with agonists of the GLP-1 receptor reduces HbA1c,
induces weight loss, has a low risk of hypoglycaemia [9–12] and
may therefore provide a useful addition to the available oral ant-
diabetic drugs. The patient-reported outcome data demonstrate
high rates of patient satisfaction with both exenatide and
liraglutide. These data show that patients prefer many aspects
of treatment satisfaction (measured by DTSQ), including
convenience and ﬂexibility, when receiving liraglutide than
when receiving exenatide. A number of factors may contribute
towards better patients’ treatment satisfaction with liraglutide:
for example, the once-daily dosing may account for improved
convenience with liraglutide, as opposed to the twice-daily
dosing before meals with exenatide; and improved ﬂexibility
with liraglutide may reﬂect the fact that daily dosing can be
administered independently of time of day or meals, as long as it
is administered approximately every 24 h. Data derived from a
quality of life questionnaire have emphasized the important
contribution of dietary freedom to overall quality of life [20]. In
addition, treatment satisfaction may be driven by the greater
reductions in fasting glucose, HbA1c levels and less frequent
hypoglycaemia with liraglutide treatment. Adverse events were
reported in 74.9% and 78.9% of patients with liraglutide and
exenatide, respectively, in LEAD 6, and nausea was more
frequent and more persistent with exenatide than with
liraglutide, and this may also inﬂuence treatment satisfaction.
Along with weight loss, patient satisfaction may improve
adherence to treatment and, thus, these patient-reported
outcome data may be an important contribution to clinical
decisions.
The results from the DTSQc scores for perceived
hyperglycaemia and hypoglycaemia may indicate that patients
feel more in control of their diabetes (i.e. they have more stable
glycaemic levels), supported by the signiﬁcantly fewer
hypoglycaemia events and improved glycaemic control (as
measured by HbA1c and fasting plasma glucose) with
liraglutide than exenatide.
The comparator drug in this study, exenatide, was previously
comparedwithinsulinglargine,wheretheDTSQwasincludedto
assess the patients’ treatment satisfaction [21]. The results
showed that exenatide and insulin glargine both improved
treatment satisfaction, but that there was no difference between
Table 1 Baseline patient and disease characteristics of the LEAD 6 ITT population and the subgroup of patients that completed the DTSQ
Variable
ITT population PRO-assessed population
Liraglutide group Exenatide group Liraglutide group Exenatide group
Men⁄women, n 114⁄119 127⁄104 94⁄98 99⁄88
Mean (sd) age, years 56.3 (9.8) 57.1 (10.8) 56.8 (10.0) 56.6 (11.1)
Mean (sd) weight, kg 93.1 (20.1) 93.0 (19.5) 93.8 (20.6) 95.0 (20.4)
Mean (sd) BMI, kg⁄m
2 32.9 (5.5) 32.9 (5.7) 33.1 (5.7) 33.5 (5.7)
Mean (sd) duration of diabetes, years 8.5 (6.2) 7.9 (5.9) 8.6 (6.3) 7.6 (5.9)
Mean (sd) HbA1c, % 8.2 (1.0) 8.1 (1.0) 8.2 (1.0) 8.1 (1.0)
Previous anti-diabetic treatment, n
Metformin 64 63 52 57
Sulphonylurea 24 21 17 14
Metformin + sulphonylurea 145 147 123 116
Mean (sd) fasting blood glucose, mmol⁄l 9.8 (2.5) 9.5 (2.4) 9.8 (2.6) 9.6 (2.5)
DTSQs score NA NA 27.4 27.6
BMI, body mass index; DTSQ, Diabetes Treatment Satisfaction Questionnaire; ITT, intention-to-treat; LEAD 6, Liraglutide Effect and
Action in Diabetes 6; NA, not applicable; PRO, patient-reported outcome.
P < 0.0001*
Weeks 0–26
Liraglutide
Exenatide-liraglutide
7
6
5
4
3
2
1
–1
0
P = 0.0026
Weeks 26–40
C
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a
n
g
e
 
i
n
 
D
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FIGURE 3 Overall treatment satisfaction, as measured by the Diabetes
Treatment Satisfaction Questionnaire status version (DTSQs), in patients
initially receiving liraglutide 1.8 mg once daily or exenatide 10 lgt w i c e
daily for 26 weeks, and then receiving liraglutide 1.8 mg once daily for
14 weeks (patient-reported outcome analysis population with data in
extension phase of trial). *Comparison of liraglutide vs. exenatide change
from baseline. Comparison of week 40 vs. week 26 in the exenatide to
liraglutide group.
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long-actingformulationofexenatidegivenonceweeklyhasbeen
shown to provide better glycaemic control than twice-daily
exenatide [22]. In that head-to-head study (a 30-week,
open-label trial that included 295 patients with Type 2
diabetes), patients’ treatment satisfaction was also measured by
the DTSQ and, although the results showed a trend towards
greater treatment satisfaction with exenatide once weekly vs.
twice daily, the difference was not statistically signiﬁcant [7].
While the open-label design of this study limits the full
interpretation of the ﬁndings, there are many reasons to believe
thattheresultsreportedherearereliable.LEAD 6isalarge,well-
controlled studywith a high proportion of patients participating
in patient-reported outcome assessments. As patient-reported
Table 2 Mean (sd) change from baseline in DTSQ scores (ITT) to end of week 26
Item
DTSQs DTSQc
Liraglutide Exenatide
Relative difference
between
treatments
(95% CI; P-value*) Liraglutide Exenatide
Relative difference
between
treatments
(95% CI; P-value*)
Current treatment
Baseline 4.4 (1.7)
(n = 188)
4.6 (1.4)
(n = 187)
Change
from baseline
1.01 (1.99)
(n = 179)
0.49 (1.82)
(n = 172)
0.37
(0.09–0.65; 0.009)
2.72 (0.69)
(n = 164)
2.39 (0.93)
(n = 144)
0.35
(0.17–0.53; 0.0002)
Convenience
Baseline 4.8 (1.3)
(n = 187)
4.7 (1.2)
(n = 187)
Change
from baseline
0.59 (1.51)
(n = 179)
0.02 (1.75)
(n = 174)
0.68
(0.41–0.92; < 0.0001)
2.47
(0.98) (n = 164)
2.10
(1.28) (n = 144)
0.40
(0.15–0.66; 0.002)
Flexibility
Baseline 4.5 (1.6)
(n = 187)
4.4 (1.5)
(n = 187)
Change
from baseline
0.70 (1.80)
(n = 179)
0.19 (1.85)
(n = 175)
0.57
(0.27–0.86; 0.0002)
2.30 (1.05)
(n = 163)
1.93 (1.34)
(n = 144)
0.38
(0.12–0.64; 0.005)
Understanding
Baseline 4.6 (1.3)
(n = 188)
4.6 (1.3)
(n = 187)
Change
from baseline
0.49 (1.19)
(n = 179)
0.38 (1.52)
(n = 174)
0.14
()0.09 to 0.36; 0.236)
2.36 (0.85)
(n = 163)
2.33
(0.91) (n = 144)
0.02
()0.17 to 0.21; 0.828)
Recommend
Baseline 4.6 (1.6)
(n = 186)
4.8 (1.4)
(n = 185)
Change
from baseline
0.96 (1.64)
(n = 178)
0.35 (1.85)
(n = 170)
0.49
(0.23–0.75; 0.0003)
2.67 (0.90)
(n = 163)
2.41 (1.02)
(n = 143)
0.28
(0.06–0.50; 0.012)
Continue
Baseline 4.4 (1.8)
(n = 186)
4.5 (1.7)
(n = 186)
Change
from baseline
1.03 (2.25)
(n = 178)
0.25 (2.35)
(n = 173)
0.66
(0.33–0.99; 0.0001)
2.71 (0.74)
(n = 163)
2.32 (1.14)
(n = 143)
0.40
(0.19–0.62; 0.0003)
Perceived hyperglycaemia
Baseline 3.8 (1.8)
(n = 185)
3.8 (1.8)
(n = 186)
Change
from baseline
)1.82 (2.16)
(n = 176)
)1.61 (2.29)
(n = 174)
)0.27
()0.63 to 0.09; 0.142)
)0.99 (1.86)
(n = 163)
)0.33 (1.93)
(n = 145)
)0.74
()1.17 to )0.31; 0.0007)
Perceived
hypoglycaemia
Baseline 1.0 (1.5)
(n = 187)
0.9 (1.4)
(n = 186)
Change
from baseline
0.06 (2.02)
(n = 179)
0.11 (1.69)
(n = 173)
)0.02
()0.32 to 0.29; 0.908)
)0.88 (1.78)
(n = 164)
)0.44 (1.80)
(n = 145)
)0.48
()0.89 to )0.08; 0.019)
*Versus exenatide group.
DTSQs scores were evaluated by LOCF methodology; DTSQc scores were analysed in the per-protocol population.
DTSQc, Diabetes Treatment Satisfaction Questionnaire change version; DTSQs, Diabetes Treatment Satisfaction Questionnaire status
version; ITT, intention to treat; LOCF, last observation carried forward.
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clinical trial process, the number of patient-reported outcome
assessmentswaslimitedtobaseline(atrandomization)andtothe
endofthetrial(week 26),butassessmentsintheextensionphase
have also provided useful longer-term data. As treatment
satisfaction was the endpoint of the study, blinding was not
feasible: different pens are used to administer liraglutide and
exenatide and the two drugs had a different dose frequency and
time of administration.
Althoughpatient-reportedoutcomeassessmentsaresubjective
and should be interpreted accordingly, the DTSQ is a validated
measure for assessing treatment satisfaction and perceived
hyperglycaemia and hypoglycaemia [17,18]. The clinical
signiﬁcance of the changes measured in DTSQ is worth
discussing. DTSQ is a measure of treatment satisfaction that
was designed explicitly to measure issues of importance to
patients and therefore any statistically signiﬁcant differences
measured by DTSQ will necessarily be an important difference
[23]. Treatment satisfaction has been shown to signiﬁcantly
correlate with the duration of diabetes and perceived blood
glucosecontrolusing the DTSQ [17]and thereliability ofDTSQ
has been demonstrated [24]. The DTSQ is highly sensitive to
major changes in treatment, for example, from tablets to
injections [25], or from conventional (more rigid insulin
regimen with ﬁxed meal times) to a more ﬂexible insulin dosing
(allowingfordietaryfreedom)[26].TheDTSQshasbeenusedto
measure treatment satisfaction during treatment with injectable
insulin [27], but the phenomenon of ceiling and ﬂoor effects
(whendataareskewed,withaproportionofrespondentshaving
optimal scores at baseline) may lead to underestimation of
treatmenteffects[28].However,the useoftheDTSQcalongside
the DTSQs should overcome this [18] and the results with both
measures were consistent in our study. The DTSQ also has
proven sensitivity when measuring differences between
treatment groups [24].
In conclusion, the clinical beneﬁts of once-daily liraglutide
over twice-daily exenatide, when used in combination with
metformin, sulphonylurea or both in people with Type 2
diabetes, are accompanied by signiﬁcant improvements in
treatment satisfaction, including the important aspects of
convenience, ﬂexibility, perceived hypoglycaemia and overall
patient satisfaction.
Table 3 Mean (sd) change from week 26 in DTSQ scores (patient-reported outcome analysis population with data in extension phase of trial) to end of
week 40 (DTSQs) or end of week 34 (all patients received liraglutide)
Item
DTSQs DTSQc
Liraglutide Exenatide
Relative difference
between
treatments
(95% CI; P-value*) Liraglutide Exenatide
Relative difference
between
treatments
(95% CI; P-value*)
Current treatment
Change from
week 26
)0.10 (0.91)
(n = 160)
0.10 (0.95)
(n = 134)
)0.20
()0.42 to 0.02; 0.070)
)0.08 (0.78)
(n = 155)
)0.02 (1.14)
(n = 131)
)0.06
()0.29 to 0.17; 0.582)
Convenience
Change from
week 26
)0.06 (1.04)
(n = 161)
0.38 (1.39)
(n = 136)
)0.47
()0.75 to )0.19; 0.001)
0.05 (1.03)
(n = 153)
0.11 (1.55)
(n = 131)
)0.08
()0.40 to 0.23; 0.592)
Flexibility
Change from
week 26
)0.07 (1.38)
(n = 161)
0.29 (1.44)
(n = 137)
)0.31
()0.63 to 0.02; 0.064)
)0.02 (1.18)
(n = 153)
0.24 (1.63)
(n = 131)
)0.23
()0.56 to 0.10; 0.173)
Understanding
Change from
week 26
0.09 (0.86)
(n = 160)
0.15 (0.92)
(n = 136)
)0.05
()0.25 to 0.16; 0.660)
)0.04 (1.03)
(n = 154)
)0.03 (0.94)
(n = 131)
)0.01
()0.24 to 0.22; 0.921)
Recommend
Change from
week 26
0.01 (0.81)
(n = 160)
0.16 (1.18)
(n = 134)
)0.17
()0.39 to 0.05; 0.138)
)0.04 (1.04)
(n = 153)
0.14 (1.07)
(n = 129)
)0.18
()0.44 to 0.07; 0.160)
Continue
Change from
week 26
)0.01
(0.69) (n = 161)
0.26 (1.22)
(n = 135)
)0.29
()0.51 to )0.06; 0.013)
)0.01 (0.72)
(n = 152)
0.08 (1.36)
(n = 129)
)0.09
()0.35 to 0.17; 0.499)
Perceived hyperglycaemia
Change from
week 26
)0.31 (1.60)
(n = 160)
)0.50 (1.92)
(n = 137)
0.23
()0.18 to 0.64; 0.264)
)0.01 (2.14)
(n = 154)
)0.44 (1.97)
(n = 131)
0.48
()0.01 to 0.98; 0.056)
Perceived hypoglycaemia
Change from
week 26
)0.21 (1.74)
(n = 161)
)0.07 (1.52)
(n = 136)
)0.11
()0.49 to 0.27; 0.582)
)0.07 (2.29)
(n = 155)
)0.34
(2.04) (n = 131)
0.34
()0.17 to 0.86; 0.191)
*Versus week 26 data.
Treatment received during the ﬁrst 26 weeks of the trial.
DTSQc, Diabetes Treatment Satisfaction Questionnaire change version; DTSQs, Diabetes Treatment Satisfaction Questionnaire status
version.
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